Table 1.
Clinical assessment post‐treatment #1 | ||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immediate post‐treatment #1 | 1‐Week follow‐up | 6‐Week follow‐up | 12‐Week follow‐up | |||||||||||||
0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | 0 | 1 | 2 | 3 | |
Blanching | 45 | 14 | 1 | 0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Bruising | 58 | 2 | 0 | 0 | 59 | 1 | 0 | 0 | 60 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Erythema/purpura | 0 | 16 | 44 | 0 | 59 | 0 | 1 | 0 | 60 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Edema/swelling | 23 | 7 | 30 | 0 | 57 | 3 | 0 | 0 | 60 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Numbness | 6 | 17 | 23 | 14 | 17 | 30 | 12 | 1 | 56 | 4 | 0 | 0 | 1 | 0 | 0 | 0 |
Tingling | 42 | 15 | 3 | 0 | 50 | 10 | 0 | 0 | 60 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
Other | 0 | 0 | 0 | 1 | 0 | 11 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |